Valuation: Dimerix Limited

Market Cap 135M 94.87M 83.25M 78.63M 71.65M 134M 9.09B 941M 364M 4.65B 356M 349M 14.93B P/E 2025
-24.3x
P/E 2026 -4.13x
Enterprise Value 119M 83.69M 73.44M 69.36M 63.21M 118M 8.02B 830M 321M 4.1B 314M 307M 13.17B EV / Sales 2025
49.4x
EV / Sales 2026 16.9x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 day-4.26%
1 week-8.16%
Current month-19.64%
1 month-28.57%
3 months+12.50%
6 months-30.77%
Current year-59.09%
1 week 0.22
Extreme 0.225
0.26
1 month 0.22
Extreme 0.225
0.31
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 27/08/2018
Director of Finance/CFO 59 29/01/2026
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 61 03/07/2015
Chairman - -
Director/Board Member - 27/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-4.26%-8.16%-56.73%+221.43% 94.87M
-0.14%+4.33%+9.88%+31.73% 47.97B
-1.69%+1.48%+53.02%+33.59% 44.5B
+2.56%+7.34%+382.17%+594.81% 43.93B
+0.24%+2.85%+9.78%+89.54% 41.03B
-0.62%-1.11%+4.70%+46.02% 29.85B
-0.28%+1.07%+26.83%+152.91% 17.27B
-0.46%+1.20%+26.78%+41.32% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+9.93% - 15.34B
Average -0.35%+1.30%+51.82%+151.42% 27.01B
Weighted average by Cap. +0.11%+2.86%+82.98%+156.24%

Financials

2025 2026
Net sales 5.59M 3.92M 3.44M 3.25M 2.96M 5.55M 376M 38.91M 15.07M 192M 14.73M 14.41M 617M 6.35M 4.46M 3.92M 3.7M 3.37M 6.31M 428M 44.25M 17.14M 218M 16.75M 16.39M 702M
Net income -13.25M -9.31M -8.17M -7.71M -7.03M -13.16M -892M -92.3M -35.75M -456M -34.94M -34.19M -1.46B -29.81M -20.94M -18.37M -17.35M -15.81M -29.6M -2.01B -208M -80.43M -1.03B -78.61M -76.91M -3.29B
Net Debt -68.19M -47.89M -42.02M -39.69M -36.17M -67.7M -4.59B -475M -184M -2.34B -180M -176M -7.54B -15.92M -11.18M -9.81M -9.27M -8.45M -15.81M -1.07B -111M -42.95M -548M -41.98M -41.08M -1.76B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
25/09/26 A$0.2250 -4.26% 605,478
24/09/26 A$0.2350 0.00% 1,094,284
23/09/26 A$0.2350 -2.08% 1,414,555
22/09/26 A$0.2400 +2.13% 305,261
21/09/26 A$0.2350 -4.08% 927,640